News

Patients with psoriatic disease face an increased risk of cardiovascular disease. Clinicians should consider this when determining management and treatment modalities for patients with psoriasis.

We've compiled all our coverage from the biggest dermatology meeting of the year to give you a thorough recap of everything you need to know or catch up on.

Allergist immunologist Giselle Mosnaim, MD, recently spoke with Dermatology Times to discuss late-breaking phase 3 REMIX-1 and REMIX-2 data presented at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.

Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between April and June. Share your thoughts with us by March 27.

A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.

The newly-established observation is a recognition of the commitment of dermatologists to serving the public and aims to bring awareness to the role of dermatology visits, skin checks, and more.

Our March 2024 publication features stories that reflect the sense of growth and newness in the specialty.

Catch up on coverage from the fifth and final day of the 2024 American Academy of Dermatology Annual Meeting.

Founder Dina El-Sherif, MBA, gave an in-depth overview of the at-home facial rejuvenation device and its 3-step process at AAD 2024.

Ronda Farah, MD, FAAD, reviews top hair loss pearls from her 5 sessions at AAD 2024.

In between sessions, Lal shared his favorite pearls from AAD, a recent challenging pediatric case in his practice, the significance of LinkedIn, and more.

Arianne Shadi Kourosh, MD, MPH, FAAD, shared pearls on environmental factors that can impact skin aging and pigmentation including visible light, IR radiation, location, and pollution.

Rebecca Hartman, MD, MPH, FAAD, and Christine Kannler, MD, FAAD, took a deep dive into considerations and pearls to treat patients who have been exposed to extreme heat and chemicals in the line of duty.

Raj Chovatiya, MD, PhD, delves into the conditions that could be red, itchy, and not atopic dermatitis. He explains the importance of knowing characteristics for various inflammatory conditions.

The Bristol Myers Squibb-hosted event brought together a panel of leading women in dermatology to discuss the challenges they’ve faced and how women can support each other.

Frey discussed the role of various cosmeceuticals and ingredients in benefitting the skin health of patients, as well as insights into pairing OTC products with Rx.

Shawn Kwatra, MD, shares positive updates on phase 2 oral povorcitinib for prurigo nodularis at AAD 2024.

Presented at the American Academy of Dermatology Annual Meeting, the poster was the winner of the third place poster award.

Swanson shared updates and a look ahead at what is in store for pediatric dermatology.

Several posters presented at the American Academy of Dermatology Annual Meeting explored the topic of skin tone bias related to vitiligo in Google and internet search platforms.

Catch up on coverage from the fourth day of the 2024 American Academy of Dermatology Annual Meeting.

Christopher Bunick, MD, PhD, presented updates and new data on the recent news of benzene found in benzoyl peroxide products.

A vote during the annual meeting will keep DEI initiatives in place and members are awaiting news on what those initiatives will look like.

Presented at the American Academy of Dermatology Annual Meeting, the poster was the winner of the second place poster award.

Naiem Issa, MD, PhD, emphasized the importance of increased awareness regarding antibiotic stewardship among dermatologists, as well as the recently updated acne guidelines.

Menes Kizoulis shared key highlights from the research conducted alongside leading dermatologists, like Alan Irvine, MD, DSc, and Patricia Farris, MD, MS.

Waibel shared pearls in laser therapy and other scar treatment modalities in her talks at the American Academy of Dermatology Annual Meeting.

The injectable polidocanol exhibited high efficacy, quicker onset of benefit, reduced downtime, and fewer side effects lasting longer than 30 days.

Mona Shahriari, MD, presented real-world data on the efficacy of IL-23 inhibitors for psoriasis, as well as shared her advice from the Bristol Myers Squibb Women’s Connection Forum.

Lio spoke with Dermatology Times to discuss his sessions at AAD 2024, including addressing systemic malignancies with alternative or adjunctive therapies and the importance of minimizing pain in dermatology procedures.